Ngozi Erondu

14.1k total citations · 4 hit papers
50 papers, 9.6k citations indexed

About

Ngozi Erondu is a scholar working on Pharmacology, Endocrinology, Diabetes and Metabolism and Physiology. According to data from OpenAlex, Ngozi Erondu has authored 50 papers receiving a total of 9.6k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pharmacology, 14 papers in Endocrinology, Diabetes and Metabolism and 10 papers in Physiology. Recurrent topics in Ngozi Erondu's work include Pharmacology and Obesity Treatment (10 papers), Psoriasis: Treatment and Pathogenesis (9 papers) and Diabetes Treatment and Management (9 papers). Ngozi Erondu is often cited by papers focused on Pharmacology and Obesity Treatment (10 papers), Psoriasis: Treatment and Pathogenesis (9 papers) and Diabetes Treatment and Management (9 papers). Ngozi Erondu collaborates with scholars based in United States, Australia and United Kingdom. Ngozi Erondu's co-authors include Mehul Desai, Kenneth W. Mahaffey, Dick de Zeeuw, David R. Matthews, Vlado Perkovic, Bruce Neal, Greg Fulcher, Wayne Shaw, Gordon Law and Mary B. Kennedy and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Ngozi Erondu

50 papers receiving 9.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

2017 5.4k citations Bruce Neal, Vlado Perkovic et al. New England Journal of Medicine profile →
Biochemical and immunochemical evidence that the "major postsynaptic density protein" is a subunit of a calmodulin-dependent protein kinase.

1983 494 citations Ngozi Erondu et al. profile →
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials

2018 468 citations Vlado Perkovic, Dick de Zeeuw et al. profile →
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events

2017 375 citations Kenneth W. Mahaffey, Bruce Neal et al. Circulation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ngozi Erondu United States	30	6.1k	3.3k	2.6k	1.4k	1.1k	50	9.6k
Morris Schambelan United States	55	3.5k 0.6×	2.9k 0.9×	1.6k 0.6×	1.7k 1.2×	549 0.5×	164	10.6k
Akira Sugawara Japan	56	1.8k 0.3×	4.7k 1.4×	1.2k 0.5×	2.6k 1.8×	512 0.5×	294	10.4k
Mark C. Chappell United States	62	5.3k 0.9×	3.4k 1.0×	1.1k 0.4×	7.8k 5.5×	1.9k 1.8×	219	13.7k
Duncan J. Campbell Australia	48	2.2k 0.4×	2.8k 0.8×	1.3k 0.5×	4.5k 3.1×	592 0.5×	172	8.3k
Nayyar Iqbal United States	36	5.1k 0.8×	2.2k 0.7×	2.0k 0.8×	807 0.6×	952 0.9×	127	7.2k
Debra I. Diz United States	57	3.2k 0.5×	2.9k 0.9×	1.1k 0.4×	6.1k 4.2×	1.4k 1.3×	219	10.3k
Winfried Siffert Germany	48	1.5k 0.2×	3.7k 1.1×	1.2k 0.4×	1.6k 1.1×	363 0.3×	262	8.4k
Jane E.B. Reusch United States	51	2.5k 0.4×	2.9k 0.9×	1.3k 0.5×	1.8k 1.2×	423 0.4×	195	8.6k
Franco Mantero Italy	65	13.8k 2.3×	2.3k 0.7×	8.7k 3.3×	2.1k 1.5×	548 0.5×	372	17.5k
John Connell United Kingdom	50	4.3k 0.7×	1.9k 0.6×	1.7k 0.6×	2.9k 2.0×	610 0.6×	179	8.7k

Countries citing papers authored by Ngozi Erondu

Since Specialization

Citations

This map shows the geographic impact of Ngozi Erondu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ngozi Erondu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ngozi Erondu more than expected).

Fields of papers citing papers by Ngozi Erondu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ngozi Erondu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ngozi Erondu. The network helps show where Ngozi Erondu may publish in the future.

Co-authorship network of co-authors of Ngozi Erondu

This figure shows the co-authorship network connecting the top 25 collaborators of Ngozi Erondu. A scholar is included among the top collaborators of Ngozi Erondu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ngozi Erondu. Ngozi Erondu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mahaffey, Kenneth W., Bruce Neal, Vlado Perkovic, et al.. (2017). Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events. Circulation. 137(4). 323–334. 375 indexed citations breakdown →

Hollander, Priscilla, Harold Bays, Julio Rosenstock, et al.. (2017). Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial. Diabetes Care. 40(5). 632–639. 90 indexed citations

Neal, Bruce, Vlado Perkovic, Kenneth W. Mahaffey, et al.. (2017). Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine. 377(7). 644–657. 5379 indexed citations breakdown →

Neal, Bruce, Vlado Perkovic, Kenneth W. Mahaffey, et al.. (2017). Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS‐R trials. Diabetes Obesity and Metabolism. 19(7). 926–935. 79 indexed citations

Mease, Philip J., Mark C. Genovese, Alex Mutebi, et al.. (2016). Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis. The Journal of Rheumatology. 43(2). 343–349. 17 indexed citations

Mease, Philip J., Mark C. Genovese, Maria Greenwald, et al.. (2015). OP0175 Two-Year Clinical Response to Brodalumab, An Anti-IL-17 Receptor Antibody, in Patients with Psoriatic Arthritis. Annals of the Rheumatic Diseases. 74. 136–137. 4 indexed citations

Mease, Philip J., Mark C. Genovese, Alex Mutebi, et al.. (2014). AB0755 Reliability and Construct Validity of the Psoriasis Symptom Inventory in Subjects with Psoriatic Arthritis. Annals of the Rheumatic Diseases. 73. 1054–1054. 1 indexed citations

Mease, Philip J., Mark C. Genovese, Maria Greenwald, et al.. (2014). Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis. New England Journal of Medicine. 370(24). 2295–2306. 308 indexed citations

Diacon, Andreas H., Rodney Dawson, Jeannine du Bois, et al.. (2012). Phase II Dose-Ranging Trial of the Early Bactericidal Activity of PA-824. Antimicrobial Agents and Chemotherapy. 56(6). 3027–3031. 109 indexed citations

10.

Proietto, Joseph, A Rissanen, Joyce B. Harp, et al.. (2010). A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study. International Journal of Obesity. 34(8). 1243–1254. 59 indexed citations

11.

Kipnes, Mark, Priscilla Hollander, Ken Fujioka, et al.. (2009). A one‐year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes. Diabetes Obesity and Metabolism. 12(6). 517–531. 43 indexed citations

12.

Wadden, T. A., Reneé H. Moore, Meghan L. Butryn, et al.. (2009). Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis. Obesity Reviews. 10(3). 333–341. 68 indexed citations

13.

Erondu, Ngozi, Carol Addy, Kaifeng Lu, et al.. (2007). NPY5R Antagonism Does Not Augment the Weight Loss Efficacy of Orlistat or Sibutramine. Obesity. 15(8). 2027–2042. 23 indexed citations

14.

Gantz, Ira, Ngozi Erondu, Madhuja Mallick, et al.. (2007). Efficacy and Safety of Intranasal Peptide YY3–36 for Weight Reduction in Obese Adults. The Journal of Clinical Endocrinology & Metabolism. 92(5). 1754–1757. 124 indexed citations

15.

Heymsfield, Steven B., Joyce B. Harp, Marc L. Reitman, et al.. (2007). Why do obese patients not lose more weight when treated with low-calorie diets? A mechanistic perspective. American Journal of Clinical Nutrition. 85(2). 346–354. 165 indexed citations

16.

Heymsfield, Steven B., Tung M. Fong, Ira Gantz, & Ngozi Erondu. (2006). Fat and Energy Partitioning: Longitudinal Observations in Leptin‐treated Adults Homozygous for a Lep Mutation. Obesity. 14(2). 258–265. 5 indexed citations

17.

Baumrucker, Craig R. & Ngozi Erondu. (2000). Insulin-Like Growth Factor (IGF) System in the Bovine Mammary Gland and Milk. Journal of Mammary Gland Biology and Neoplasia. 5(1). 53–64. 73 indexed citations

18.

Erondu, Ngozi & John E. Donelson. (1991). Characterization of trypanosome protein phosphatase 1 and 2A catalytic subunits. Molecular and Biochemical Parasitology. 49(2). 303–314. 29 indexed citations

19.

Erondu, Ngozi & J E Donelson. (1990). Characterization of a myosin-like antigen from Onchocerca volvulus. Molecular and Biochemical Parasitology. 40(2). 213–224. 23 indexed citations

20.

Lucius, Richard, Ngozi Erondu, A Kern, & J E Donelson. (1988). Molecular cloning of an immunodominant antigen of Onchocerca volvulus.. The Journal of Experimental Medicine. 168(3). 1199–1204. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact